二甲双胍与腹主动脉瘤关系的研究综述
本文综述了二甲双胍与腹主动脉瘤(AAA)关联的现有证据。流行病学研究提示二甲双胍等降糖药与AAA呈负相关,基于其对主动脉壁代谢与炎症的作用,文中讨论了转化应用及临床试验前景。
要点
- 流行病学提示二甲双胍与腹主动脉瘤呈负相关
- 二甲双胍对代谢和炎症反应的作用是其潜在治疗基础
- 需临床试验验证二甲双胍用于AAA患者管理的价值
核心结论
- 流行病学研究显示二甲双胍使用与腹主动脉瘤呈负相关,但其治疗价值尚待临床试验验证。
研究设计与样本
- 综述类文章,总结二甲双胍与腹主动脉瘤关联的现有知识及转化应用与临床试验。
主要发现
- 流行病学研究强调包括二甲双胍在内的降糖药使用与腹主动脉瘤呈负相关。
- 二甲双胍对代谢和炎症反应的作用使其被提议为多种心血管疾病的潜在治疗靶点。
临床怎么用
- 基于二甲双胍对主动脉壁的已知效应,讨论其在腹主动脉瘤患者管理中的转化应用与临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Abdominal aortic aneurysm (AAA) is a life-threatening disease and pharmacologic agents to treat the disease remain lacking for clinical practice. Epidemiologic studies have highlighted a negative association between the use of antidiabetic drugs, including metformin, and AAA. Metformin is well-known for its blood glucose-lowering effect, but its action on both metabolism and inflammatory response has led to propose it as a potential therapeutic target in several cardiovascular diseases. In this review, we summarize the current knowledge on the link between metformin and AAA. Based on the known effects of the drug on the aortic wall, translational applications and clinical trials investigating the interest of metformin in the management of patients with AAA are discussed.
引用
- Raffort J, Hassen-Khodja R, Jean-Baptiste E, et al. Relationship between metformin and abdominal aortic aneurysm. J Vasc Surg. 2019. PMID: 31727461. doi:10.1016/j.jvs.2019.08.270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。